Diversity of Epitope and Cytokine Profiles for Primary and Secondary Influenza a Virus-specific CD8+ T Cell Responses
Overview
Authors
Affiliations
Screening with the flow cytometric IFN-gamma assay has led to the identification of a new immunogenic peptide (SSYRRPVGI) [corrected] from the influenza PB1 polymerase (PB1(703--711)) and a mimotope (ISPLMVAYM) from the PB2 polymerase (PB2(198--206)). CD8(+) T cells specific for K(b)PB1(703) make both IFN-gamma and TNF-alpha following stimulation with both peptides. The CD8(+) K(b)PB1(703)(+) population kills PB2(198)-pulsed targets, but cell lines stimulated with PB2(198) neither bind the K(b)PB1(703) tetramer nor become CTL. This CD8(+)K(b)PB1(703)(+) population is prominent in the primary response to an H3N2 virus, although it is much less obvious following secondary challenge of H1N1-primed mice. Even so, we can now account for >40% of the CD8(+) T cells in a primary influenza pneumonia and >85% of those present after H3N2 --> H1N1 challenge. Profiles of IFN-gamma and TNF-alpha staining following in vitro stimulation have been traced for the four most prominent influenza peptides through primary and secondary responses into long-term memory. The D(b)NP(366) epitope that is immunodominant after the H3N2 --> H1N1 challenge shows the lowest frequencies of CD8(+) IFN-gamma(+)TNF-alpha(+) cells for >6 wk, and the intensity of IFN-gamma staining is also low for the first 3 wk. By 11 wk, however, the IFN-gamma/TNF-alpha profiles look to be similar for all four epitopes. At least by the criterion of cytokine production, there is considerable epitope-related functional diversity in the influenza virus-specific CD8(+) T cell response. The results for the K(b)PB1(703) epitope and the PB2(198) mimotope also provide a cautionary tale for those using the cytokine staining approach to identity antigenic peptides.
Vieira Antao A, Oltmanns F, Schmidt A, Viherlehto V, Irrgang P, Rameix-Welti M Front Immunol. 2024; 15:1376395.
PMID: 38975350 PMC: 11224462. DOI: 10.3389/fimmu.2024.1376395.
Kim S, Espano E, Padasas B, Son J, Oh J, Webby R Immune Netw. 2024; 24(3):e19.
PMID: 38974213 PMC: 11224667. DOI: 10.4110/in.2024.24.e19.
Lanfermeijer J, van de Ven K, Hendriks M, van Dijken H, Lenz S, Vos M Vaccines (Basel). 2024; 12(4).
PMID: 38675801 PMC: 11054904. DOI: 10.3390/vaccines12040419.
Ng T, Flores-Malavet V, Mansoor M, Arvelo A, Dhume K, Prokop E J Immunol. 2023; 210(5):628-639.
PMID: 36645384 PMC: 9998374. DOI: 10.4049/jimmunol.2200393.
Divide and Conquer: Phenotypic and Temporal Heterogeneity Within CD8 T Cell Responses.
Richard A Front Immunol. 2022; 13:949423.
PMID: 35911755 PMC: 9334874. DOI: 10.3389/fimmu.2022.949423.